Refine by
Novel Moa Neurotransmitter Equipment & Supplies
1 equipment items found
by:Relmada Therapeutics, Inc. based inCoral Gables, FLORIDA (USA)
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major Depressive Disorder (MDD). REL-1017 works with a MOA markedly different from standard serotoninergic ...